Nanobiotix S.A. (LON: 0QAV)
London
· Delayed Price · Currency is GBP · Price in EUR
3.110
-0.072 (-2.26%)
Jan 23, 2025, 9:35 AM BST
Nanobiotix Employees
Nanobiotix had 102 employees as of December 30, 2023. The number of employees did not change compared to the previous year.
Employees
102
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
325.29K GBP
Profits / Employee
-257.99K GBP
Market Cap
127.33M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 89,900 |
GSK plc | 70,212 |
Haleon | 25,408 |
Smith & Nephew | 18,452 |
ConvaTec Group | 10,136 |
Hikma Pharmaceuticals | 9,100 |
HUTCHMED (China) | 1,988 |
Oxford Nanopore Technologies | 1,238 |
Nanobiotix News
- 5 weeks ago - NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024 - GlobeNewsWire
- 6 weeks ago - NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer - GlobeNewsWire
- 2 months ago - NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms - GlobeNewsWire
- 3 months ago - NANOBIOTIX to Participate in Multiple Investor Conferences in November - GlobeNewsWire
- 4 months ago - NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results - GlobeNewsWire
- 5 months ago - NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth - GlobeNewsWire
- 5 months ago - Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 8 months ago - NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024 - GlobeNewsWire